Immunotherapy combo shows promise for rare, aggressive breast cancer
Disease control
Ongoing
This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before surgery can improve outcomes for people with HER2-negative inflammatory breast cancer, a rare and aggressive form of the disease. About 52 participants will receive either chemo a…
Phase: PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC